Jade Biosciences Announces New Preclinical Data on JADE101 for IgA Nephropathy at 62nd ERA Congress

Reuters

06-02

<a href="https://laohu8.com/S/JBIO">Jade Biosciences</a> Announces New Preclinical Data on JADE101 for IgA Nephropathy at 62nd ERA Congress

Jade Biosciences, Inc., a biotechnology company specializing in autoimmune disease therapies, announced the presentation of new preclinical data on its anti-APRIL monoclonal antibody, JADE101, at the 62nd European Renal Association Congress. The data, aimed at treating IgA nephropathy (IgAN), will be shared during a Focused Oral Session on Glomerular and Tubulo-Interstitial Diseases in Vienna on June 6, 2025. The presentation, led by Erin Filbert, Executive Director and Head of Research and Translational Medicine at Jade Biosciences, will focus on the discovery and characterization of JADE101. Following the congress, Jade Biosciences plans to host a conference call and webcast on June 9, 2025, at 8:00 a.m. ET to discuss the findings. Investors and the public can register for the event on the company's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461324-en) on June 02, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540762701"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540762701\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540762701?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540762701","market":"us","top_or_hot":-1,"title":"Jade Biosciences Announces New Preclinical Data on JADE101 for IgA Nephropathy at 62nd ERA Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/JBIO\">Jade Biosciences</a> Announces New Preclinical Data on JADE101 for IgA Nephropathy at 62nd ERA Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jade Biosciences, Inc., a biotechnology company specializing in autoimmune disease therapies, announced the presentation of new preclinical data on its anti-APRIL monoclonal antibody, JADE101, at the 62nd European Renal Association Congress. The data, aimed at treating IgA nephropathy (IgAN), will be shared during a Focused Oral Session on Glomerular and Tubulo-Interstitial Diseases in Vienna on June 6, 2025. The presentation, led by Erin Filbert, Executive Director and Head of Research and Translational Medicine at Jade Biosciences, will focus on the discovery and characterization of JADE101. Following the congress, Jade Biosciences plans to host a conference call and webcast on June 9, 2025, at 8:00 a.m. ET to discuss the findings. Investors and the public can register for the event on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461324-en) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jade Biosciences Announces New Preclinical Data on JADE101 for IgA Nephropathy at 62nd ERA Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJade Biosciences Announces New Preclinical Data on JADE101 for IgA Nephropathy at 62nd ERA Congress\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-02 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/JBIO\">Jade Biosciences</a> Announces New Preclinical Data on JADE101 for IgA Nephropathy at 62nd ERA Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jade Biosciences, Inc., a biotechnology company specializing in autoimmune disease therapies, announced the presentation of new preclinical data on its anti-APRIL monoclonal antibody, JADE101, at the 62nd European Renal Association Congress. The data, aimed at treating IgA nephropathy (IgAN), will be shared during a Focused Oral Session on Glomerular and Tubulo-Interstitial Diseases in Vienna on June 6, 2025. The presentation, led by Erin Filbert, Executive Director and Head of Research and Translational Medicine at Jade Biosciences, will focus on the discovery and characterization of JADE101. Following the congress, Jade Biosciences plans to host a conference call and webcast on June 9, 2025, at 8:00 a.m. ET to discuss the findings. Investors and the public can register for the event on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461324-en) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL25JFkg:1","article_id":"2540762701","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540762701","pubTimestamp":1748862040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jade Biosciences, Inc., a biotechnology company specializing in autoimmune disease therapies, announced the presentation of new preclinical data on its anti-APRIL monoclonal antibody, JADE101, at the 62nd European Renal Association Congress. The data, aimed at treating IgA nephropathy , will be shared during a Focused Oral Session on Glomerular and Tubulo-Interstitial Diseases in Vienna on June 6, 2025. The presentation, led by Erin Filbert, Executive Director and Head of Research and Translational Medicine at Jade Biosciences, will focus on the discovery and characterization of JADE101. Following the congress, Jade Biosciences plans to host a conference call and webcast on June 9, 2025, at 8:00 a.m. ET to discuss the findings. Investors and the public can register for the event on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Jade Biosciences在第62届ERA大会上公布了JADE101治疗IgA肾病的新临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JBIO":0.9,"NDAQ":0.9},"content_text":"Jade Biosciences Announces New Preclinical Data on JADE101 for IgA Nephropathy at 62nd ERA Congress\n    \n\n        Jade Biosciences, Inc., a biotechnology company specializing in autoimmune disease therapies, announced the presentation of new preclinical data on its anti-APRIL monoclonal antibody, JADE101, at the 62nd European Renal Association Congress. The data, aimed at treating IgA nephropathy (IgAN), will be shared during a Focused Oral Session on Glomerular and Tubulo-Interstitial Diseases in Vienna on June 6, 2025. The presentation, led by Erin Filbert, Executive Director and Head of Research and Translational Medicine at Jade Biosciences, will focus on the discovery and characterization of JADE101. Following the congress, Jade Biosciences plans to host a conference call and webcast on June 9, 2025, at 8:00 a.m. ET to discuss the findings. Investors and the public can register for the event on the company's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461324-en) on June 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}